Dispatches
The Eternal Journal
Daily notes from Eternal Search: development work, news with an actual angle, graph connections, and idea pathways. No ceremonial optimism required.
Fahy and Metformin: a caloric-restriction thread
Gregory Fahy's profile is linked to metformin via a finding that eight weeks of treatment reproduced caloric-restriction-like gene-expression changes better than a comparator called CR8, though the original study and Fahy's role remain unknown.
Andrea Maier and NMN: study parameters, no outcomes yet
Andrea Maier, Oon Chiew Seng Professor in Medicine at the National University of Singapore, is linked to NMN through a study excerpt describing 80 middle-aged participants given 300, 600, or 900 mg daily for 60 days; her role and the study's outcomes are no...
Andrea Maier and NAD Metabolism
A trial excerpt supports linking Andrea Maier's profile to NAD metabolism through blood measurements before and after NMN supplementation, but provides neither results nor her role in the trial.
Mehmood Khan and Metformin: the frailty data
Look AHEAD frailty data grounds the Hevolution Foundation CEO's connection to metformin, one of geroscience's best-evidenced longevity candidates.
Jamie Justice and Senolytics
Jamie Justice's geroscience work on biomarkers and clinical trial design connects her to both the D+Q nonhuman-primate senolytic trial and the first-in-human senolytics study, placing her at the boundary between preclinical signal and human evidence.
Jamie Justice and Caloric Restriction
Jamie Justice's profile references an 18-week caloric restriction trial in 58 adults with obesity and prediabetes (10.8 kg mean weight loss, circulating SASP factors measured), but her role in the trial and the significance of the SASP-factor changes for bi...
Jamie Justice and Dasatinib
Jamie Justice's geroscience work on clinical biomarkers connects to the D+Q senolytic protocol tested monthly in nonhuman primates for six months.
Jamie Justice and the D+Q Senolytic Link
Jamie Justice's connection to quercetin traces to a source citing the senolytic combination dasatinib plus quercetin, though her specific role or study is not established.
FLP-17 links glial stress sensing to remote UPR activation
The neuropeptide FLP-17 activates the Unfolded Protein Response in distant C. elegans tissues through glial signaling, a cell-nonautonomous proteostasis mechanism linked to Jennifer Garrison's research on brain-organ communication.
Rubedo Life Sciences' Senolytic Patent
Patent US11026963B2, granted to Rubedo Life Sciences in 2021, describes chemical compositions for selectively killing senescent cells; which compositions carry enforceable protection and whether any has reached human trials remain unestablished from availab...
Navitoclax and sickle cell disease: senolytic hypothesis from St. Jude
A pending St. Jude patent proposes treating sickle cell disease by targeting senescent cells and reports navitoclax restored HSC function in SCD mice; the available excerpt provides no dose, sample size, statistical analysis, or human evidence.
St. Jude Patent Proposes Senolytics for Sickle Cell Disease
A pending St. Jude patent proposes treating sickle cell disease complications with senolytic drugs that selectively eliminate senescent cells; the accessible excerpt does not specify agents, doses, or experimental results.
CAR-T Cells as Senolytics: Targeting uPAR
A 2020 Memorial Sloan Kettering patent application proposes engineered CAR-T cells targeting the surface protein uPAR for selective elimination of senescent cells, placing an immune-cell modality within the senolytic intervention class.
WO2018215795A2: Selective Killing as the Senolytic Criterion
A 2018 patent application from United Kingdom Research and Innovation defines senolytic compounds as agents that selectively kill senescent cells over non-senescent cells, proposing a mechanism through altered signaling pathways that restore or trigger apop...
NAC and glycine: the Baylor glutathione patent
A 2016 WIPO patent from Pharmaplan LLC and Baylor College of Medicine describes a glycine-plus-N-acetylcysteine composition for restoring glutathione levels, with claimed benefits in oxidative stress, mitochondrial fuel oxidation, and mouse lifespan that th...
Glycine paired with NAC to raise glutathione
A 2016 patent publication from Pharmaplan LLC and Baylor College of Medicine describes glycine paired with N-acetylcysteine as a precursor strategy to raise intracellular glutathione levels.
Firmenich patent: AKG against age-associated body odor
Firmenich SA patent CN115996696A proposes alpha-ketoglutarate as a peroxide-reducing ingredient in fragrance formulations intended to limit age-associated body odor; the available excerpt shows POV reduction in oils and fragrance materials.
2003: TOR Signaling Linked to Aging in Nematodes
The Wikipedia timeline of aging research records the first evidence in 2003 that TOR signaling regulates aging in nematodes.
Metformin and the 2007 mouse lifespan finding
The Wikipedia aging research timeline marks 2007 as the year of first evidence that metformin, a diabetes drug, could extend mouse lifespan; the source describes metformin as a longevity candidate linked to the proposed TAME trial but provides no human life...
NMN in the Aging Research Timeline
The Wikipedia 'Timeline of aging research' references NMN as an NAD+ precursor, but the available excerpt provides no further context on which study or result is being discussed.
Insulin/IGF-1 signaling and human longevity genetics
A 2009 entry in the Wikipedia Timeline of aging research records an association between insulin/IGF-1 signaling variants and human longevity; causality was not established.
Rapamycin's 2009 Mouse Result and the Human Evidence Gap
The Wikipedia Timeline of aging research records 2009 as the year rapamycin was shown to extend mouse lifespan; human evidence remains limited to survey studies and a single 48-week trial in healthy adults.
AMPK and the 2004 Nematode Entry
The Wikipedia Timeline of aging research records a 2004 finding that AMP-kinase regulates nematode aging, but the study's authors, design, and mechanism are not established from the available data.
Hayano Lab's Lens Elasticity Finding and Resveratrol
A study co-authored by Hayano Lab members reports that oral resveratrol improved lens elasticity, but the experimental model, dose, and clinical implications remain unknown from the available data.
Timeline enters XPRIZE Healthspan top 100 with Urolithin A
Timeline made the XPRIZE Healthspan top 100 with a Urolithin A product described as a mitophagy activator; formulation, dose, and clinical endpoints are not detailed in the source.
Senolytics Under Scrutiny: De Magalhães and an Open Question
Our system connects João Pedro de Magalhães to senolytics through a source titled 'Senolytics under scrutiny in the quest to slow aging,' but his specific role in the source and his views on senolytic efficacy are unavailable.
Aubrey de Grey and Antagonistic Pleiotropy
A source in Aubrey de Grey's dossier cites growing evidence for antagonistic pleiotropy in mammalian aging, though whether de Grey authored or endorsed the claim is not clear from available data.
Fedichev on Rapamycin: Claim Without Context
Peter Fedichev's texts cite rapamycin as a TOR inhibitor and as part of a combination that produced the greatest lifespan-extending effect, but the combination's composition and experimental model are not disclosed.
Zhavoronkov and senomorphics: INS018_055 as TNIK kinase inhibitor
Alex Zhavoronkov is linked to the senomorphics class through work on INS018_055, a TNIK kinase inhibitor classified as a senomorphic agent because it reduced SASP, the senescence-associated secretory phenotype.
Ferrucci and caloric restriction: the human question
Luigi Ferrucci connects to caloric restriction through the two-year CALERIE trial, while caloric restriction's effects on humans remain an open question.
Anar Isman, AgelessRx, and rapamycin
Anar Isman is linked to rapamycin with high confidence; stored evidence mentions AgelessRx, which paired prescription-therapy access with rapamycin-trial participation.
George Church: Combination Gene Therapy
Church-associated programs use AAV delivery of longevity-associated genes (FGF21, αKlotho, soluble TGF-β receptor 2) to treat multiple age-related diseases, with combination gene therapy proposed as a route to improved health span and longevity; Rejuvenate ...
Kenyon's daf-2 and the First Life-Extension Pathway
Cynthia Kenyon's daf-2 work helped define insulin/IGF-1 signaling as the first life-extension pathway; in the knowledge graph her node connects to eight related terms and four projects investigating IIS.
Guarente and the Sirtuin Axis
Leonard Guarente helped establish sirtuins and metabolic regulation as major longevity mechanisms; sirtuin signaling is the NAD-dependent pathway coupling energy status to chromatin regulation, metabolism, stress responses, and tissue maintenance.
Guarente → NAD Metabolism: the sirtuin-NAD bridge
Leonard Guarente's link to NAD Metabolism (0.99 confidence) rests on evidence that he helped make sirtuins and NAD biology unavoidable in longevity research; three nodes overlap between his graph neighbors and the term's cluster, suggesting a bridge role.
Klotho and the Age Window
Fabrisia Ambrosio co-authored a 2021 eLife study showing that systemic Klotho overexpression improved muscle strength in old mice but produced no functional improvement in oldest-old mice, with the boundary linked to an entropy inflection point in aging-hal...
Brigham XPRIZE and NMN: The Connection Traces to a Screening Patent
Eternal Search links the Brigham Boston XPRIZE Healthspan team to NMN through an aging-agent screening patent from Centre for Translational Stem Cell Biology; the same project maps to eight other compounds, placing NMN in a broader screening context.
NMN Anti-Aging Patent: Filed 2015, Abandoned
A 2015 US patent application on using NMN in anti-aging preparations was published in 2017; its Google Patents status is now Abandoned.
CN113621009A: beta-NMN chemical synthesis patent
A 2021 Chinese patent application from Chongqing Daxin Pharmaceutical and Peking University affiliates describes a chemical synthesis method for beta-NMN, an NAD precursor.
David Sinclair: Wikipedia Authorship Label Unsupported
Sinclair's Wikipedia biography carries an authorship label the source does not support; the article describes him and connects in the graph to resveratrol, NMN, and epigenetic rejuvenation.
OpenDrugs, Rapamycin, and the Zero-Target Metric
OpenDrugs investigates rapamycin as one of 3,100 indexed compounds, but reports 0 biological targets and full provenance for roughly 70–75 longevity-associated substances, pointing to broad coverage with limited depth.
Nicotinamide Riboside in a Parkinson’s Patent
A Parkinson’s patent publication explicitly names nicotinamide riboside, but the dossier does not establish dose, route, disease stage, patient group, or clinical support.
Japan Longevity Consortium → Nicotinamide Riboside
A confidence-1 graph edge ties Japan Longevity Consortium to nicotinamide riboside, with stored evidence naming a 2000 mg/day high-dose regimen for at least 5 days.
George Church: Authorship, Not Aura
A direct authorship edge links George M. Church’s Eternal Search investor profile to a specific PubMed publication, with evidence shown as “Church George M.” and confidence 1.